Literature DB >> 24818875

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update.

Yasuo Suzuki1, Hajime Nawata, Satoshi Soen, Saeko Fujiwara, Hisanori Nakayama, Ikuko Tanaka, Keiichi Ozono, Akira Sagawa, Ryoichi Takayanagi, Hiroyuki Tanaka, Takami Miki, Naomi Masunari, Yoshiya Tanaka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24818875     DOI： 10.1007/s00774-014-0586-6

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN： 0914-8779            Impact factor:   2.626


× No keyword cloud information.
  50 in total

1.  Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

Authors:  Hajime Nawata; Satoshi Soen; Ryoichi Takayanagi; Ikuko Tanaka; Kunio Takaoka; Masao Fukunaga; Toshio Matsumoto; Yasuo Suzuki; Hiroyuki Tanaka; Saeko Fujiwara; Takami Miki; Akira Sagawa; Yoshiki Nishizawa; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

2.  Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

Authors:  C Roux; P Oriente; R Laan; R A Hughes; J Ittner; S Goemaere; O Di Munno; J M Pouillès; S Horlait; B Cortet
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

3.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

4.  Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.

Authors:  J D Ringe; A Cöster; T Meng; E Schacht; R Umbach
Journal:  Calcif Tissue Int       Date:  1999-10       Impact factor: 4.333

5.  Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan.

Authors:  Masahiro Urade; Noriaki Tanaka; Kiyofumi Furusawa; Jun Shimada; Takanori Shibata; Tadaaki Kirita; Tetsuya Yamamoto; Tetsuro Ikebe; Yoshimasa Kitagawa; Jinichi Fukuta
Journal:  J Oral Maxillofac Surg       Date:  2011-07-23       Impact factor: 1.895

6.  The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.

Authors:  Shreyasee Amin; Michael P Lavalley; Robert W Simms; David T Felson
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

7.  Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; J Preuss
Journal:  Rheumatology (Oxford)       Date:  2003-04-16       Impact factor: 7.580

8.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

Authors:  S Aubrey Stoch; Kenneth G Saag; Maria Greenwald; Anthony I Sebba; Stanley Cohen; Nadia Verbruggen; Hilde Giezek; Joseph West; Thomas J Schnitzer
Journal:  J Rheumatol       Date:  2009-06-01       Impact factor: 4.666
View more
  33 in total

1.  Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study.

Authors:  Yoshiya Tanaka; Hiroko Mori; Takatoshi Aoki; Tatsuya Atsumi; Yutaka Kawahito; Hisanori Nakayama; Shigeto Tohma; Yuji Yamanishi; Hitoshi Hasegawa; Kazuhide Tanimura; Nobuo Negoro; Yukitaka Ueki; Atsushi Kawakami; Katsumi Eguchi; Kazuyoshi Saito; Yosuke Okada
Journal:  J Bone Miner Metab       Date:  2015-08-26       Impact factor: 2.626

Review 2.  Glucocorticoid-induced osteoporosis: 2019 concise clinical review.

Authors:  G Adami; K G Saag
Journal:  Osteoporos Int       Date:  2019-02-25       Impact factor: 4.507

3.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

Review 4.  Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.

Authors:  Pojchong Chotiyarnwong; Eugene V McCloskey
Journal:  Nat Rev Endocrinol       Date:  2020-04-14       Impact factor: 43.330

5.  Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation.

Authors:  Shuhei Kurosawa; Noriko Doki; Yasushi Senoo; Yuya Kishida; Akihito Nagata; Yuta Yamada; Tatsuya Konishi; Satoshi Kaito; Kota Yoshifuji; Naoki Matsuyama; Shuichi Shirane; Tomoyuki Uchida; Kyoko Inamoto; Takashi Toya; Aiko Igarashi; Yuho Najima; Hideharu Muto; Takeshi Kobayashi; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi
Journal:  Ann Hematol       Date:  2020-05-25       Impact factor: 3.673

6.  Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.

Authors:  K Moriwaki; H Fukuda
Journal:  Osteoporos Int       Date:  2019-01-04       Impact factor: 4.507

7.  Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.

Authors:  Mai Kawazoe; Kaichi Kaneko; Kotaro Shikano; Natsuko Kusunoki; Toshihiro Nanki; Shinichi Kawai
Journal:  Clin Rheumatol       Date:  2017-05-27       Impact factor: 2.980

Review 8.  Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

9.  Lower trabecular bone score is associated with an increased incidence of localized femoral periosteal thickening.

Authors:  Hiroe Sato; Naoki Kondo; Yoichi Kurosawa; Eriko Hasegawa; Ayako Wakamatsu; Daisuke Kobayashi; Takeshi Nakatsue; Junichiro James Kazama; Takeshi Kuroda; Yoshiki Suzuki; Naoto Endo; Ichiei Narita
Journal:  J Bone Miner Metab       Date:  2021-07-20       Impact factor: 2.626

10.  Evaluation of myostatin as a possible regulator and marker of skeletal muscle-cortical bone interaction in adults.

Authors:  Nagato Kuriyama; Etsuko Ozaki; Teruhide Koyama; Daisuke Matsui; Isao Watanabe; Satomi Tomida; Reo Nagamitsu; Kanae Hashiguchi; Masaaki Inaba; Shinsuke Yamada; Motoyuki Horii; Shigeto Mizuno; Yutaro Yoneda; Masao Kurokawa; Daiki Kobayashi; Shinpei Fukuda; Koichi Iwasa; Yoshiyuki Watanabe; Ritei Uehara
Journal:  J Bone Miner Metab       Date:  2020-10-12       Impact factor: 2.626
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.